Figure 3.
Percentage of US and non-US participants on treatment with liraglutide or placebo during the LEADER trial (30). Full analysis set. US, United States.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.